An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient

Tolga Şahin, Ayfer Serin

Department of Internal Medicine, Division of Gastroenterology, Demiroğlu Bilim University Medicine Faculty, Istanbul, Turkey

ABSTRACT
Hepatocellular carcinoma (HCC) is the fifth common cancer and the second cause of cancer-related death worldwide. Hepatitis C virus (HCV) is a common cause of chronic hepatitis, liver cirrhosis, and HCC. Recently, some new drugs have been developed named direct-acting antivirals (DAAs) for chronic HCV treatment. Direct-acting antivirals provide sustained viral response and total cure in over 80% of chronic hepatitis C patients. In this article, we present a patient with HCV genotype 1b-induced cirrhosis with giant HCC development after ledipasvir/sofosbuvir combination therapy. Although chronic hepatitis C infection can be cured with the combination of new generation DAAs, HCC pathogenesis and development risk in cirrhotic cases are still unclear. Thus, cirrhotic patients treated with DAAs should be followed-up at close intervals after treatment.

Keywords: Hepatitis C virus; hepatocellular carcinoma; ledipasvir; sofosbuvir.

CASE REPORT
The patient is a 58-year-old female with past medical history of CHC infection, cholecystectomy, urolithiasis, and ovarian cyst operation. She had HCC development after ledipasvir/sofosbuvir combination therapy. One year following the treatment, she was found to have a giant HCC in the right lobe of liver without virus reactivation.

Liver cancer development after antiviral therapy in a HCV patient

no information about how she acquired hepatitis C virus. She denied suspicious sexual intercourses, intravenous drug use, and/or tattoo history. She had no history of alcohol consumption either. She had CHC-induced compensated cirrhosis, and the combination of pegylated interferon and ribavirin treatment was unsuccessful several years ago. She applied to our liver transplantation unit three years ago with compensated liver cirrhosis without HCC. Her model for end-stage liver disease (MELD) score was low and alpha-fetoprotein levels were normal; hence, transplantation was delayed. Follow-up at three-month intervals was established, after which the patient was observed at another medical center during the following three years. She had ledipasvir/sofosbuvir therapy for three months at this center a year ago, after which the patient did not apply to any facility for follow-up. The patient applied with the complaints of weakness and weight loss to the external medical center, after which a giant HCC was detected on portal computed tomography (CT) scan in the right lobe of the liver. Patient was referred to our hepatobiliary diseases unit for treatment. We performed a panel of laboratory tests, CT scans, dynamic abdominal magnetic resonance imaging (MRI), and positron emission tomography. Her alpha-fetoprotein level was 63.315 ng/mL, hepatitis C virus (HCV) ribonucleic acid (RNA) was negative, and liver transaminase levels were within the normal range. A giant HCC lesion almost completely filling the right lobe was observed. She had also a satellite HCC nodule in the left lobe of the liver with a diameter of approximately 3 cm. Portal vein thrombosis associated with the HCC was observed on abdominal imaging and she was out of the Milan criteria for liver transplantation. The patient was found inoperable for transplantation at the liver transplantation council and referred to the medical oncology council, who decided to perform trans-arterial radioembolization treatment for the patient (Figure 1 and 2). A written informed consent was obtained from the patient.

**DISCUSSION**

Hepatitis C virus is a hepatotropic RNA virus estimated to infect approximately 71 million people worldwide. Hepatitis C virus can be the cause of chronic hepatitis, liver cirrhosis, and HCC.[1] In patients with untreated CHC, 20% of cases progress to cirrhosis, while 1-4% of them develop HCC.[2] Over the past few years, several direct-acting agents (DAAs) have been developed that target some proteins in the critical stages of the HCV lifecycle. Combination of two or three DAAs can totally cure CHC infection in 95% of genotype 1 patients.[3]

Side effects of DAAs are controversial, particularly in cirrhotic cases. The number of cases described to develop HCC after treatment with DAAs in the literature is increasing. According to current knowledge, HCC development

![Figure 1. Giant hepatocellular carcinoma lesion in right lobe of liver in computed tomography scan.](image1)

![Figure 2. Giant hepatocellular carcinoma lesion on the right lobe of liver in positron emission tomography/computed tomography scan.](image2)
mechanisms are quite complex. The etiology of HCC includes multiple mechanisms, while the presence of liver cirrhosis is a key factor for the development of HCC. Hepatitis C virus also has the potential to stimulate oncological pathways, regardless of cirrhosis. Treatment with DAAs leads to a very rapid decrease in HCV RNA levels. Rapid and sudden disappearance of chronic inflammation due to chronic hepatitis may lead to rapid and uncontrolled proliferation of hepatocytes or stimulate some unknown oncological pathways which may lead to HCC development.

Direct-acting antivirals are suggested for patients with MELD score of lower than 12 in cirrhotic patients; however, the relationship between HCC development and DAAs is unclear. Even if HCV is fully eradicated, the risk of developing HCC continues in patients with cirrhosis. Thus, these patients should be closely monitored at intervals of 12 weeks or less after the treatment.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

REFERENCES